{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:08:27Z","timestamp":1778710107675,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","award":["0601564411"],"award-info":[{"award-number":["0601564411"]}],"id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["MCRF16022"],"award-info":[{"award-number":["MCRF16022"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1049818"],"award-info":[{"award-number":["GNT1049818"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","award":["1127757"],"award-info":[{"award-number":["1127757"]}],"id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","award":["6253"],"award-info":[{"award-number":["6253"]}],"id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001043","name":"Cass Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001215","name":"La Trobe University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["IIRS-18-026"],"award-info":[{"award-number":["IIRS-18-026"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bcp.2021.114410","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T16:36:32Z","timestamp":1610296592000},"page":"114410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A switch in mechanism of action prevents doxorubicin-mediated cardiac damage"],"prefix":"10.1016","volume":"185","author":[{"given":"Alison","family":"Cheong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruqaya","family":"Maliki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Spurling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Rephaeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda S.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9938","key":"10.1016\/j.bcp.2021.114410_b0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0010","first-page":"76","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials","volume":"24","author":"Henderson","year":"2013","journal-title":"Breast Dis."},{"issue":"8","key":"10.1016\/j.bcp.2021.114410_b0015","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114410_b0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: what the cardiologist needs to know","volume":"7","author":"Ewer","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114410_b0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"issue":"13","key":"10.1016\/j.bcp.2021.114410_b0030","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2013.201","article-title":"Topoisomerase 2\u03b2: A promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","volume":"95","author":"Vejpongsa","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2021.114410_b0040","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114410_b0045","first-page":"424","article-title":"Doxorubicin-induced cardiomyopathy 17 years after chemotherapy","volume":"39","author":"Kumar","year":"2012","journal-title":"Tex. Heart Inst. J."},{"issue":"5","key":"10.1016\/j.bcp.2021.114410_b0050","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bcp.2021.114410_b0055","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.bcp.2021.114410_b0060","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase II beta-mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2021.114410_b0065","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2174\/1568026615666150413154512","article-title":"Potential therapeutic advantages of doxorubicin when activated by formaldehyde to function as a DNA adduct-forming agent","volume":"15","author":"Cutts","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2021.114410_b0070","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/jm049428p","article-title":"The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters","volume":"48","author":"Nudelman","year":"2005","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bcp.2021.114410_b0075","first-page":"8194","article-title":"Molecular basis for the synergistic interaction of Adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9)","volume":"61","author":"Cutts","year":"2001","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.bcp.2021.114410_b0080","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1158\/1535-7163.MCT-06-0551","article-title":"Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate","volume":"6","author":"Cutts","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.bcp.2021.114410_b0085","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1158\/0008-5472.CAN-05-3410","article-title":"Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death","volume":"66","author":"Swift","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2021.114410_b0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bcp.2014.01.023","article-title":"A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo","volume":"88","author":"Tarasenko","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114410_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031393","article-title":"Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor","volume":"7","author":"Tarasenko","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10637-010-9542-z","article-title":"The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity","volume":"30","author":"Tarasenko","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0223-5234(00)01199-5","article-title":"Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases","volume":"36","author":"Nudelman","year":"2001","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1541-7786.1.3.1","article-title":"Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix","volume":"3","author":"Eckhardt","year":"2005","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ijc.2910490113","article-title":"Derivatives of butyric-acid as potential antineoplastic agents","volume":"49","author":"Rephaeli","year":"1991","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2021.114410_b0120","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/bjc.1997.151","article-title":"An anti cancer derivative of butyric acid (pivalyloxymethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells","volume":"75","author":"Kasukabe","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2021.114410_b0125","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.bjc.6603781","article-title":"Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity","volume":"96","author":"Rephaeli","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2021.114410_b0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopha.2011.06.005","article-title":"Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity","volume":"65","author":"Zhu","year":"2011","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bcp.2021.114410_b0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12012-014-9306-7","article-title":"Microarray and co-expression network analysis of genes associated with acute doxorubicin cardiomyopathy in mice","volume":"15","author":"Wei","year":"2015","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.bcp.2021.114410_b0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tox.2015.04.009","article-title":"Gene expression profiling identifies the novel role of immunoproteasome in doxorubicin-induced cardiotoxicity","volume":"333","author":"Zhao","year":"2015","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.bcp.2021.114410_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.bcp.2021.114410_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15104","article-title":"DNA single-strand break-induced DNA damage response causes heart failure","volume":"8","author":"Higo","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114410_b0155","article-title":"Open source bioimage informatics tools for the analysis of DNA damage and associated biomarkers","volume":"4","author":"Schneider","year":"2019","journal-title":"J. Lab. Precis. Med."},{"issue":"5","key":"10.1016\/j.bcp.2021.114410_b0160","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2119\/molmed.2011.00466","article-title":"Aldehyde dehydrogenase-2 deficiency aggravates cardiac dysfunction elicited by endoplasmic reticulum stress induction","volume":"18","author":"Liao","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2021.114410_b0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mito.2016.05.003","article-title":"Accurate quantification of mouse mitochondrial DNA without co-amplification of nuclear mitochondrial insertion sequences","volume":"29","author":"Malik","year":"2016","journal-title":"Mitochondrion"},{"issue":"4","key":"10.1016\/j.bcp.2021.114410_b0170","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.4990","article-title":"Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion","volume":"243","author":"Duivenvoorden","year":"2017","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114410_b0175","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2615","article-title":"ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67","volume":"12","author":"Tuominen","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2021.114410_b0180","article-title":"The RIN: an RNA integrity number for assigning integrity values to RNA measurements","volume":"7","author":"Schroeder","year":"2006","journal-title":"BMC Mol. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114410_b0185","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt214","article-title":"The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote","volume":"41","author":"Liao","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bcp.2021.114410_b0195","doi-asserted-by":"crossref","first-page":"Article3","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat. Appl. Genet Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.bcp.2021.114410_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists","volume":"37","author":"Huang","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.bcp.2021.114410_b0210","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2021.114410_b0215","first-page":"1789","article-title":"Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis","volume":"60","author":"Arola","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2021.114410_b0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","article-title":"Oxidative stress injury in doxorubicin-induced cardiotoxicity","volume":"307","author":"Mei","year":"2019","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2021.114410_b0225","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.redox.2014.12.011","article-title":"Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: Focusing on mitochondria","volume":"4","author":"Zhong","year":"2015","journal-title":"Redox Biol."},{"issue":"18","key":"10.1016\/j.bcp.2021.114410_b0230","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1158\/1078-0432.CCR-13-3373","article-title":"Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity","volume":"20","author":"Khiati","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bcp.2021.114410_b0235","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-14-0821","article-title":"Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage","volume":"20","author":"Nitiss","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2021.114410_b0240","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/nar\/28.4.1019","article-title":"Interstrand cross-linking by Adriamycin in nuclear and mitochondrial DNA of MCF-7 cells","volume":"28","author":"Cullinane","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.bcp.2021.114410_b0245","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane((R))) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114410_b0250","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2021.114410_b0255","first-page":"18","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.bcp.2021.114410_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00434","article-title":"Molecular mechanisms of cardiomyocyte death in drug-induced cardiotoxicity","volume":"8","author":"Ma","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114410_b0265","first-page":"1916","article-title":"New signal transduction paradigms in anthracycline-induced cardiotoxicity","volume":"1863","author":"Ghigo","year":"2016","journal-title":"BBA"},{"issue":"5","key":"10.1016\/j.bcp.2021.114410_b0270","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/01926230490502601","article-title":"Oxidative damage precedes nitrative damage in Adriamycin-induced cardiac mitochondrial injury","volume":"32","author":"Chaiswing","year":"2004","journal-title":"Toxicol. Pathol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114410_b0275","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous-infusion","volume":"96","author":"Legha","year":"1982","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.bcp.2021.114410_b0280","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1","article-title":"Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts","volume":"73","author":"Vaage","year":"1994","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2021.114410_b0285","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminoncol.2004.08.002","article-title":"Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies","volume":"31","author":"Vail","year":"2004","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114410_b0290","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00280-007-0528-2","article-title":"The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity","volume":"61","author":"Swift","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.bcp.2021.114410_b0295","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<379::AID-DDR20>3.0.CO;2-8","article-title":"Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action, and clinical applications","volume":"50","author":"Rephaeli","year":"2000","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bcp.2021.114410_b0300","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.taap.2016.02.003","article-title":"Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice","volume":"295","author":"Vijay","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114410_b0305","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/893106","article-title":"The multifaceted functions of CXCL10 in cardiovascular disease","author":"van den Borne","year":"2014","journal-title":"Biomed Res. Int."},{"issue":"12","key":"10.1016\/j.bcp.2021.114410_b0310","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4161\/cbt.11.12.15540","article-title":"Doxorubicin and daunorubicin induce processing and release of interleukin-1 beta through activation of the NLRP3 inflammasome","volume":"11","author":"Sauter","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2021.114410_b0315","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tips.2015.03.006","article-title":"Arginase: an old enzyme with new tricks","volume":"36","author":"Caldwell","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2021.114410_b0320","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1096\/fj.03-0724rev","article-title":"The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage","volume":"18","author":"Fogli","year":"2004","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.bcp.2021.114410_b0325","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/taap.2002.9527","article-title":"Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation","volume":"185","author":"Aldieri","year":"2002","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114410_b0330","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.2001.890305.x","article-title":"Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy","volume":"89","author":"Sayed-Ahmed","year":"2001","journal-title":"Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114410_b0335","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.tcm.2012.10.003","article-title":"Transcriptional regulation of macrophage arginase 1 expression and its role in atherosclerosis","volume":"23","author":"Pourcet","year":"2013","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.bcp.2021.114410_b0340","article-title":"The role of macrophages in the infarcted myocardium: orchestrators of ECM remodeling","volume":"6","author":"O\u2019Rourke","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"issue":"9B","key":"10.1016\/j.bcp.2021.114410_b0345","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1111\/j.1582-4934.2009.00707.x","article-title":"Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction","volume":"13","author":"Troidl","year":"2009","journal-title":"J. Cell Mol. Med."},{"issue":"7669","key":"10.1016\/j.bcp.2021.114410_b0350","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature23481","article-title":"Mammals divert endogenous genotoxic formaldehyde into one-carbon metabolism","volume":"548","author":"Burgos-Barragan","year":"2017","journal-title":"Nature"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522100006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522100006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:13:50Z","timestamp":1778706830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522100006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":70,"alternative-id":["S000629522100006X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114410","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A switch in mechanism of action prevents doxorubicin-mediated cardiac damage","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114410"}}